Compare MAMA & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MAMA | NKTX |
|---|---|---|
| Founded | 2010 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 602.1M | 198.2M |
| IPO Year | 2011 | 2020 |
| Metric | MAMA | NKTX |
|---|---|---|
| Price | $12.78 | $2.57 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 7 |
| Target Price | ★ $22.29 | $10.83 |
| AVG Volume (30 Days) | ★ 750.9K | 582.0K |
| Earning Date | 09-03-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 44.44 | 11.88 |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $95,420,129.00 | N/A |
| Revenue This Year | $30.28 | N/A |
| Revenue Next Year | $12.49 | N/A |
| P/E Ratio | $129.00 | ★ N/A |
| Revenue Growth | ★ 95.54 | N/A |
| 52 Week Low | $9.90 | $1.70 |
| 52 Week High | $21.00 | $3.72 |
| Indicator | MAMA | NKTX |
|---|---|---|
| Relative Strength Index (RSI) | 35.48 | 42.51 |
| Support Level | $12.89 | $2.28 |
| Resistance Level | $14.97 | $3.29 |
| Average True Range (ATR) | 0.65 | 0.17 |
| MACD | 0.01 | -0.05 |
| Stochastic Oscillator | 12.90 | 10.00 |
Mama's Creations Inc manufactures and markets fresh deli-prepared foods distributed through grocery, mass, club, and convenience stores across the United States. Its product portfolio includes refrigerated prepared foods such as meatballs, meatloaf, sausage products, and pasta and rice entrees. The products are principally sold to supermarkets, club chains, mass-market retailers, and food distributors. The brand of the company includes Mama's Creations, Mama's Mancini's, The Olive Branch, Creative Salads, and others.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK-cell expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.